Results 121 to 130 of about 55,599 (265)

DOMINANT BUSINESS MODELS IN THE GLOBAL PHARMACEUTICAL INDUSTRY

Economics & Education, 2019
The research is dedicated to the analyses of existing business models in pharmaceutical industry, their strength and weaknesses. The first generation of corporate business models in the global pharmaceutical sector are the traditional closed business ...
Roman Simonov
doaj  

Revisiting the Carbon Footprint of Single‐Use Technologies in Biomanufacturing: A Bottom‐Up Analysis Reveals a Paradigm Shift

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The biopharmaceutical industry increasingly relies on single‐use technologies (SUT) for operational flexibility. For a long time, SUT was considered more sustainable than stainless‐steel (SST) systems due to water and energy savings. This study re‐evaluates this paradigm via a detailed bottom‐up analysis of the SUT carbon footprint at the 2000 
Jan Reiners, Katharina Bruno‐Thakur, Daina Romeo, Weronika Kuśmierczyk, Ferdinand Stückler   +4 more
wiley   +1 more source

Technological and industrial trends in China's pharmaceutical sector. [PDF]

Front Pharmacol
Wang J, He M, Lu F, Chen Y, Wang H.
europepmc   +1 more source

Pectinase‐Based Bioprocesses for Circular Bioeconomy and Sustainable Industrial Development

Biotechnology and Bioengineering, EarlyView.
This picture demonstrates a unified strategy for sustainable pectinase production, focusing on microbial bioproduction, innovative strategies in enzyme engineering (Protein engineering, rational enzyme design, directed evolution and heterologous expression) and various applications in industry, including food, textiles, pulp and paper, agriculture and ...
Nisha Sharma, Dimple Tanwar, Usha Grewal, Murugesan Mohana Keerthi, Yogesh K. Ahlawat, Nitin Pandey, Chirag G. Makvana   +6 more
wiley   +1 more source

Ethiopian Pharmaceutical Sector Stakeholder Perspectives on Regulatory Harmonization in IGAD: A Descriptive Study. [PDF]

Inquiry
Marew T, Belete A, Richmond FJ, Gebre-Mariam T.   +3 more
europepmc   +1 more source

Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study. [PDF]

Risk Manag Healthc Policy, 2019
Ebadi Fardazar F, Sarabi Asiabar A, Safari H, Asgari M, Saber A, Ebadi Fard Azar AA.   +5 more
europepmc   +1 more source

A Business Framework for Product Take‐Back—A Structured Multiple‐Case Analysis

Business Strategy and the Environment, EarlyView.
ABSTRACT The potential of take‐back systems remains largely unrealized as initiatives have proven difficult to implement in practice. The question is why we do not see more take‐back systems given the substantial environmental benefits. We try to understand the challenges and stumbling blocks in setting up take‐back from a business perspective.
Rasmus Jørgensen, Torben Pedersen
wiley   +1 more source

Marine-Derived Compounds Combined with Nanoparticles: A Focus on the Biomedical and Pharmaceutical Sector. [PDF]

Mar Drugs
Teixeira LM, Reis CP, Pacheco R.
europepmc   +1 more source

Green Innovation and Firm Efficiency: The Role of Institutional Quality in Italian High‐Tech Manufacturing Sectors

Business Strategy and the Environment, EarlyView.
ABSTRACT The aim of this research is to verify whether institutional quality affects the relationship between green innovation and firm efficiency within the high‐tech manufacturing sectors. To estimate jointly the parameters of a stochastic frontier and the coefficients of a model explaining technical inefficiency, we employed the one‐step estimation ...
Mariarosaria Agostino, Sandro Rondinella, Marianna Succurro   +2 more
wiley   +1 more source

Soft Skills, Strong Results: The Impact on Medical Representatives in the Saudi Pharmaceutical Sector. [PDF]

J Res Pharm Pract
Qashlan M, Halawany K, Ali M, Ahmad O, Halawani Z.   +4 more
europepmc   +1 more source